annb0t
Top 20
Valneva SE VALN, a specialty vaccine company, recently reported positive Phase 3 - VLA1553-321 data in adolescents (12 to 17 years old) for its single-shot chikungunya virus (CHIKV) vaccine, IXCHIQ. For investorsâ note, IXCHIQ is the worldâs first and only licensed chikungunya vaccine available to address this significant unmet medical need.
The trial data supports and strengthens the pivotal data previously reported for adolescents in the United States, Europe and Canada. Data from t...
>>> Read more: Favorable VLA1553-321 Phase 3 Study Results Boost VALN Stock
The trial data supports and strengthens the pivotal data previously reported for adolescents in the United States, Europe and Canada. Data from t...
>>> Read more: Favorable VLA1553-321 Phase 3 Study Results Boost VALN Stock
